IL199725A - Antibody preparations containing anti-human recombinant epidermal growth factor receptor, a kit containing them, specific bio-specific binding molecules and their uses - Google Patents

Antibody preparations containing anti-human recombinant epidermal growth factor receptor, a kit containing them, specific bio-specific binding molecules and their uses

Info

Publication number
IL199725A
IL199725A IL199725A IL19972509A IL199725A IL 199725 A IL199725 A IL 199725A IL 199725 A IL199725 A IL 199725A IL 19972509 A IL19972509 A IL 19972509A IL 199725 A IL199725 A IL 199725A
Authority
IL
Israel
Prior art keywords
specefic
kit
growth factor
factor receptor
epidermal growth
Prior art date
Application number
IL199725A
Other languages
English (en)
Hebrew (he)
Other versions
IL199725A0 (en
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39495833&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL199725(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Symphogen As filed Critical Symphogen As
Publication of IL199725A0 publication Critical patent/IL199725A0/en
Publication of IL199725A publication Critical patent/IL199725A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL199725A 2007-03-01 2009-07-07 Antibody preparations containing anti-human recombinant epidermal growth factor receptor, a kit containing them, specific bio-specific binding molecules and their uses IL199725A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200700317 2007-03-01
US90477307P 2007-03-05 2007-03-05
DKPA200701016 2007-07-10
US92972707P 2007-07-11 2007-07-11
PCT/DK2008/050047 WO2008104183A2 (en) 2007-03-01 2008-02-27 Recombinant anti-epidermal growth factor receptor antibody compositions

Publications (2)

Publication Number Publication Date
IL199725A0 IL199725A0 (en) 2010-04-15
IL199725A true IL199725A (en) 2015-06-30

Family

ID=39495833

Family Applications (2)

Application Number Title Priority Date Filing Date
IL199725A IL199725A (en) 2007-03-01 2009-07-07 Antibody preparations containing anti-human recombinant epidermal growth factor receptor, a kit containing them, specific bio-specific binding molecules and their uses
IL216850A IL216850A (en) 2007-03-01 2011-12-08 Recombinant antibody preparations for epidermal growth factor

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL216850A IL216850A (en) 2007-03-01 2011-12-08 Recombinant antibody preparations for epidermal growth factor

Country Status (18)

Country Link
US (3) US7887805B2 (OSRAM)
EP (2) EP2132229B1 (OSRAM)
JP (1) JP5726417B2 (OSRAM)
KR (2) KR101805140B1 (OSRAM)
CN (2) CN101675075B (OSRAM)
AU (1) AU2008221118B2 (OSRAM)
BR (1) BRPI0808551B1 (OSRAM)
CA (1) CA2676049C (OSRAM)
DK (1) DK2132229T3 (OSRAM)
ES (1) ES2582386T3 (OSRAM)
HK (1) HK1197252A1 (OSRAM)
IL (2) IL199725A (OSRAM)
MX (2) MX2009008909A (OSRAM)
NZ (2) NZ597466A (OSRAM)
PL (1) PL2132229T3 (OSRAM)
RU (1) RU2013119724A (OSRAM)
TW (1) TWI426083B (OSRAM)
WO (1) WO2008104183A2 (OSRAM)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ATE521704T1 (de) * 2007-03-01 2011-09-15 Symphogen As Verfahren zur klonierung verwandter antikörper
KR101805140B1 (ko) 2007-03-01 2017-12-05 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
WO2009030239A1 (en) * 2007-09-06 2009-03-12 Genmab A/S Novel methods and antibodies for treating cancer
US20090203038A1 (en) * 2007-12-27 2009-08-13 Abbott Laboratories Negative Mimic Antibody For Use as a Blocking Reagent In BNP Immunoassays
EP2331689A4 (en) * 2008-08-29 2012-10-31 Symphogen As METHOD OF CLONING AVIAN ORIGIN ANTIBODIES
RU2540146C2 (ru) * 2008-08-29 2015-02-10 Симфоген А/С Композиции рекомбинантных антител против рецептора эпидермального фактора роста
US20110224094A1 (en) * 2008-10-06 2011-09-15 Symphogen A/S Method for identifying and selecting drug candidates for combinatorial drug products
FR2942928B1 (fr) 2009-03-03 2011-04-01 Alcatel Lucent Procede et systeme de gestion multicriteres de notifications de presence
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
US8821879B2 (en) 2009-09-04 2014-09-02 Xoma Technology Ltd. Anti-botulism antibody coformulations
CN102687020A (zh) * 2009-10-09 2012-09-19 西福根有限公司 利用特征肽和质谱对混合物中的单个重组蛋白进行多重定量
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
WO2011137114A1 (en) * 2010-04-26 2011-11-03 Abraxis Bioscience, Llc Sparc binding antibodies and uses thereof
KR20130060223A (ko) * 2010-05-04 2013-06-07 메리맥 파마슈티컬즈, 인크. 상피세포 성장인자 수용체(ｅｇｆｒ)에 대한 항체 및 이의 용도
WO2011140151A1 (en) * 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
WO2012018260A1 (en) * 2010-08-05 2012-02-09 Universiteit Utrecht Holding B.V. Epidermal growth factor receptor targeted immune therapy
AU2011320314B2 (en) 2010-10-29 2015-08-06 Immunogen, Inc. Novel EGFR-binding molecules and immunoconjugates thereof
AU2011320318B9 (en) 2010-10-29 2015-11-19 Immunogen, Inc. Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
KR101862832B1 (ko) * 2010-11-01 2018-05-30 심포젠 에이/에스 Ｐａｎ―ｈｅｒ 항체 조성물
US9155802B2 (en) * 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
EP2668209B8 (en) 2011-01-24 2021-08-11 Gilead Sciences, Inc. Antibodies selective for cells presenting egfr at high density
KR20190107761A (ko) 2011-03-09 2019-09-20 셀 시그널링 테크놀러지, 인크. 모노클로날 항체를 생성하는 방법 및 시약
CN103562226A (zh) 2011-03-11 2014-02-05 梅里麦克制药股份有限公司 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌
CA2828043A1 (en) 2011-03-15 2012-09-20 Merrimack Pharmaceuticals, Inc. Overcoming resistance to erbb pathway inhibitors
US20120258502A1 (en) * 2011-04-08 2012-10-11 Vinod Pandiripally Method of producing recombinant plasmid dna using substantially solid growth medium
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
SG11201402343SA (en) 2011-11-21 2014-06-27 Immunogen Inc Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
JP2015509091A (ja) * 2012-01-09 2015-03-26 ザ スクリプス リサーチ インスティテュート ヒト化抗体
HK1202431A1 (en) 2012-05-02 2015-10-02 Symphogen A/S Humanized pan-her antibody compositions
US20140065655A1 (en) * 2012-09-05 2014-03-06 Scivax Corporation Screening method for substance acting on maintenance of epithelial properties of cell
US20150293105A1 (en) * 2012-10-26 2015-10-15 The University Of Queensland Methods for classifying tumors and uses therefor
CN102993305B (zh) * 2012-11-16 2015-05-13 上海赛伦生物技术有限公司 人源抗人表皮生长因子受体抗体及其编码基因与应用
US9856319B2 (en) * 2012-12-28 2018-01-02 Abbvie Inc. Monovalent binding proteins
CN104059148B (zh) * 2013-03-18 2016-09-07 回而生医药科技（北京）有限公司 人源化抗人表皮生长因子受体抗体及其应用
WO2015038984A2 (en) * 2013-09-12 2015-03-19 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
WO2015112749A2 (en) * 2014-01-22 2015-07-30 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for antibody and antibody-loaded dendritic cell mediated therapy
GB201402591D0 (en) * 2014-02-14 2014-04-02 Memo Therapeutics Ag Method for recovering two or more genes, or gene products, encoding an immunoreceptor
ES2884930T3 (es) * 2014-03-26 2021-12-13 Siemens Healthcare Diagnostics Inc Inmunoensayo de canalización de oxígeno luminiscente utilizando tres anticuerpos y métodos de producción y uso de los mismos
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
WO2016065456A1 (en) * 2014-10-31 2016-05-06 Formation Biologics Inc. Egfr antibody-based combination therapy
PL3253865T3 (pl) * 2015-02-06 2022-10-10 National University Of Singapore Sposoby wzmacniania skuteczności terapeutycznych komórek odpornościowych
HK1250736A1 (zh) 2015-04-24 2019-01-11 Merrimack Pharmaceuticals, Inc. 用三种完全人类单克隆抗egfr抗体的组合治疗具有表皮生长因子受体(egfr)的胞外结构域的突变的患者的方法
AU2017235450A1 (en) 2016-03-15 2018-08-16 Merrimack Pharmaceuticals, Inc. Methods for treating ER+, HER2-, HRG+ breast cancer using combination therapies comprising an anti-ErbB3 antibody
CA3025162A1 (en) * 2016-05-26 2017-11-30 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
CA3029902A1 (en) 2016-07-07 2018-01-11 The Board Of Trustees Of The Leland Stanford Junior University Antibody adjuvant conjugates
JP7778468B2 (ja) 2016-11-22 2025-12-02 ナショナル ユニバーシティ オブ シンガポール Ｔ細胞悪性腫瘍の免疫療法のためのｃｄ７発現およびキメラ抗原受容体の遮断
MX2019007356A (es) * 2016-12-23 2019-09-05 Visterra Inc Polipeptidos de union y metodos para fabricarlos.
CA3054381A1 (en) * 2017-02-22 2018-08-30 University Of Saskatchewan Egfr-binding agents and uses thereof
WO2018166119A1 (zh) * 2017-03-14 2018-09-20 北京伟峰益民科技有限公司 一种多肽或其衍生物及其在制备治疗肿瘤的药物中的应用
SG11202000402PA (en) 2017-08-10 2020-02-27 Nat Univ Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
EP3695013A1 (en) 2017-08-30 2020-08-19 Symphogen A/S Compositions and methods for treating cancer with anti-egfr antibodies
CN109912716B (zh) * 2017-12-13 2022-08-23 凯惠科技发展(上海)有限公司 一种egfr抗体及其制备方法和应用
BR112020015142A2 (pt) * 2018-01-25 2021-01-05 Pdi Therapeutics, Inc. Anticorpos mica/b e métodos de uso
AU2019275076B2 (en) 2018-05-23 2024-12-19 National University Of Singapore Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
US11274035B2 (en) 2019-04-24 2022-03-15 X-Celeprint Limited Overhanging device structures and related methods of manufacture
US12162747B2 (en) 2018-12-03 2024-12-10 X-Celeprint Limited Enclosed cavity structures
US10456776B1 (en) 2019-02-21 2019-10-29 King Saud University Method of fabricating a photocatalyst for water splitting
JP2022525594A (ja) 2019-03-15 2022-05-18 ボルト バイオセラピューティクス、インコーポレーテッド Ｈｅｒ２を標的とする免疫結合体
CN111018990A (zh) * 2020-02-10 2020-04-17 张喜田 一种新型的重组抗表皮生长因子受体单克隆抗体及其应用
JP2024537840A (ja) 2021-10-04 2024-10-16 レ ラボラトワール セルヴィエ Ｎｋｇ２ａを標的化する癌療法
AR127893A1 (es) 2021-12-10 2024-03-06 Servier Lab Terapia del cáncer dirigida a egfr

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) * 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4943533A (en) * 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
AU4128089A (en) * 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5459061A (en) * 1990-01-26 1995-10-17 W. Alton Jones Cell Science Center, Inc. Hybridomas producing monoclonal antibodies which specifically bind to continuous epitope on the human EGF receptor and compete with EGF for binding to the EGF receptor
ATE247168T1 (de) 1991-03-06 2003-08-15 Merck Patent Gmbh Humanisierte monoklonale antikörper
KR100269879B1 (ko) 1992-06-30 2000-10-16 폴 에이치. 피셔 항-이알비비-2모노클로날항체의 조합물 및 그 사용방법
GB9401182D0 (en) 1994-01-21 1994-03-16 Inst Of Cancer The Research Antibodies to EGF receptor and their antitumour effect
WO1996040210A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US7060808B1 (en) 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
CN1432064A (zh) 2000-03-23 2003-07-23 格林维尔医院系统公司 双功能癌症治疗剂
CA2409361A1 (en) * 2000-05-19 2001-11-22 Scancell Limited Humanised antibodies to the epidermal growth factor receptor
US6849259B2 (en) * 2000-06-16 2005-02-01 Symphogen A/S Polyclonal antibody composition for treating allergy
CN100488563C (zh) 2001-02-19 2009-05-20 默克专利有限公司 免疫原性降低的经修饰抗egfr抗体
JP4414142B2 (ja) 2001-05-11 2010-02-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 特異的結合タンパク質およびその使用
US7595378B2 (en) 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
AU2002345673B2 (en) * 2001-06-13 2007-04-26 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
WO2003012072A2 (en) * 2001-08-03 2003-02-13 The Trustees Of The University Of Pennsylvania Monoclonal antibodies to activated erbb family members and methods of use thereof
EP1482043A4 (en) 2002-03-01 2005-08-10 Japan Enviro Chemicals Ltd FOR BINDING TO ENVIRONMENTAL MORNES, PROTEINS AND METHOD FOR THE PRODUCTION THEREOF
WO2003097086A2 (en) 2002-05-15 2003-11-27 Technische Universität München Egf receptor antagonists in the treatment of gastric cancer
WO2003099205A2 (en) 2002-05-20 2003-12-04 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr
EP2263691B1 (en) 2002-07-15 2012-08-29 F.Hoffmann-La Roche Ag Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
SI1523496T1 (sl) 2002-07-18 2011-11-30 Merus B V Rekombinantno proizvajanje zmesi protiteles
CA2501818C (en) 2002-10-10 2012-03-27 Merck Patent Gesellschaft Mit Beschraenkter Haftung Pharmaceutical compositions directed to erb-b1 receptors
US20060275766A1 (en) * 2003-01-07 2006-12-07 Haurum John S Method for manufacturing recombinant polyclonal proteins
NZ541458A (en) 2003-01-07 2006-04-28 Symphogen As Method for manufacturing recombinant polyclonal proteins
CA2450289A1 (en) 2003-03-20 2005-05-19 Imclone Systems Incorporated Method of producing an antibody to epidermal growth factor receptor
AT500651B9 (de) 2003-05-27 2010-04-15 Altropus Gmbh Aktiv immunisierender antikörper
TWI333977B (en) 2003-09-18 2010-12-01 Symphogen As Method for linking sequences of interest
US7655751B2 (en) 2004-01-23 2010-02-02 Green Peptide Co., Ltd. Epidermal growth factor receptor-derived peptides
US20110142822A1 (en) 2004-06-14 2011-06-16 Kussie Paul H Crystal of egfr extracellular domain and cetuximab fab fragment, and uses thereof
CA2574146C (en) * 2004-07-20 2015-06-30 Symphogen A/S A procedure for structural characterization of a recombinant polyclonal protein or a polyclonal cell line
WO2006007850A1 (en) 2004-07-20 2006-01-26 Symphogen A/S Anti-rhesus d recombinant polyclonal antibody and methods of manufacture
KR20200058588A (ko) 2005-01-21 2020-05-27 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
US20070009972A1 (en) * 2005-02-16 2007-01-11 Ginger Chao Epidermal growth factor receptor polypeptides and antibodies
MY152164A (en) 2005-02-23 2014-08-15 Genentech Inc Extending time to disease progression or survival in cancer patients
EA013617B1 (ru) 2005-02-24 2010-06-30 Амген Инк. Мутации рецептора эпидермального фактора роста
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
WO2006110478A2 (en) 2005-04-11 2006-10-19 Novartis Ag Mutations and polymorphisms of epidermal growth factor receptor
RU2007141067A (ru) 2005-04-14 2009-05-20 Мерк Патент ГмбХ (DE) Терапия с помощью антител к egfr, основанная на повышенном числе копий гена egfr в опухолевых тканях
EP1877083A2 (en) 2005-04-27 2008-01-16 Welson Pharmaceuticals, Inc. Antibodies for the treatment of cancers
RS54271B1 (sr) * 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
CA2614766A1 (en) * 2005-07-11 2007-01-18 Macrogenics, Inc. Methods of treating autoimmune disease using humanized anti-cd16a antibodies
AU2006322445B2 (en) 2005-12-05 2011-05-12 Symphogen A/S Anti-orthopoxvirus recombinant polyclonal antibody
US7498142B2 (en) 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
KR20080113223A (ko) 2006-03-06 2008-12-29 심포젠 에이/에스 호흡기세포 융합 바이러스 감염 치료용 재조합 폴리클로날 항체
KR101805140B1 (ko) * 2007-03-01 2017-12-05 심포젠 에이/에스 재조합 항-표피 성장 인자 수용체 항체 조성물
ATE521704T1 (de) 2007-03-01 2011-09-15 Symphogen As Verfahren zur klonierung verwandter antikörper
JP2008289483A (ja) * 2007-05-25 2008-12-04 Symphogen As 真核生物系において発現可能な形質転換体のスクリーニング
RU2540146C2 (ru) * 2008-08-29 2015-02-10 Симфоген А/С Композиции рекомбинантных антител против рецептора эпидермального фактора роста
US9155802B2 (en) 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition

Also Published As

Publication number Publication date
KR20100014722A (ko) 2010-02-10
CA2676049C (en) 2018-04-10
MX2009008909A (es) 2009-08-28
IL216850A (en) 2014-06-30
TWI426083B (zh) 2014-02-11
KR101805140B1 (ko) 2017-12-05
WO2008104183A3 (en) 2008-11-13
AU2008221118A1 (en) 2008-09-04
BRPI0808551B1 (pt) 2022-04-05
US7887805B2 (en) 2011-02-15
EP2132229A2 (en) 2009-12-16
CN101675075B (zh) 2014-06-18
MX338151B (es) 2016-04-05
PL2132229T3 (pl) 2016-12-30
NZ578943A (en) 2012-09-28
JP5726417B2 (ja) 2015-06-03
EP2725036B1 (en) 2017-10-25
US20090004192A1 (en) 2009-01-01
CN104151430A (zh) 2014-11-19
TW200902552A (en) 2009-01-16
AU2008221118B2 (en) 2013-10-03
US20110129855A1 (en) 2011-06-02
KR101676622B1 (ko) 2016-11-17
WO2008104183A2 (en) 2008-09-04
EP2132229B1 (en) 2016-05-11
HK1134826A1 (zh) 2010-06-11
HK1197252A1 (en) 2015-01-09
CA2676049A1 (en) 2008-09-04
CN101675075A (zh) 2010-03-17
JP2010535012A (ja) 2010-11-18
KR20160132132A (ko) 2016-11-16
US8414896B2 (en) 2013-04-09
IL199725A0 (en) 2010-04-15
IL216850A0 (en) 2012-01-31
ES2582386T3 (es) 2016-09-12
BRPI0808551A2 (pt) 2014-08-19
RU2013119724A (ru) 2014-11-10
EP2725036A1 (en) 2014-04-30
NZ597466A (en) 2013-08-30
DK2132229T3 (en) 2016-06-20
US20110135636A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
IL199725A (en) Antibody preparations containing anti-human recombinant epidermal growth factor receptor, a kit containing them, specific bio-specific binding molecules and their uses
IL265854A (en) Antigen binding proteins capable of binding thymic subset of lymphopoietin
IL205569A0 (en) Wise binding antibodies and epitopes
IL195037A0 (en) Binding proteins that bind hepatocyte growth factor
IL206188A0 (en) Antigen binding proteins
IL245666A0 (en) Interleukin-13 binding proteins
IL204757A0 (en) Heparin - binding epidermal growth factor - like growth factor antigen binding proteins
IL234081B (en) Antibody binds cd3–epsilon in different species
LT3165539T (lt) Il-17 receptoriaus a antigenus surišantys baltymai
IL201340A (en) Antidote 3dc - epsilon in various species
IL205545A0 (en) Monoclonal antibody capable of binding to anexelekto, and use thereof
IL232009A (en) Protein isolate heterodimer alpha 4 in cell 7 specific antigen-binding and various aspects thereof
ZA201303003B (en) Single-chain multivalent binding proteins with effector function
IL195038A0 (en) Hepatocyte growth factor binding proteins
EP2069401A4 (en) MULTISPECIENT EPITOP BINDING PROTEINS AND THEIR USE
IL202259A0 (en) Antigen binding proteins that bind par-2
SI1899377T1 (sl) Humanizirana protitelesa, specifična za NOGO-A, in njihove farmacevtske uporabe
HK1147764A (en) Wise binding antibodies and epitopes
HK1147763A (en) Antigen binding proteins
IL182717A0 (en) Antibodies to interferon - ??/?? binding protein
AU2013200711B2 (en) Interleukin -13 binding proteins
AU2007901644A0 (en) Novel Telomerase Peptide and Antibody
ZA201000706B (en) Antigen binding proteins that bind par-2
HK1145505A (en) Anti-chikungunya monoclonal antibodies and uses thereof
AU2007900058A0 (en) Recombinant Antibodies

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed